Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Gross Margin (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Gross Margin for 16 consecutive years, with 7.26% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 1169.0% to 7.26% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 57.1% through Dec 2025, up 206.0% year-over-year, with the annual reading at 57.1% for FY2025, 206.0% up from the prior year.
  • Gross Margin hit 7.26% in Q4 2025 for Cumberland Pharmaceuticals, down from 88.08% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 145.63% in Q4 2022 to a low of 18.95% in Q4 2024.
  • Historically, Gross Margin has averaged 67.62% across 5 years, with a median of 80.36% in 2022.
  • Biggest five-year swings in Gross Margin: soared 8536bps in 2022 and later crashed -10260bps in 2024.
  • Year by year, Gross Margin stood at 60.26% in 2021, then skyrocketed by 142bps to 145.63% in 2022, then tumbled by -43bps to 83.64% in 2023, then plummeted by -123bps to 18.95% in 2024, then soared by 62bps to 7.26% in 2025.
  • Business Quant data shows Gross Margin for CPIX at 7.26% in Q4 2025, 88.08% in Q3 2025, and 81.44% in Q2 2025.